Cirrhosis medication is not a single drug or even a single category of drugs. It is a layered treatment strategy that starts with addressing whatever caused the liver damage, then branches into managing the complications that cirrhosis produces as it progresses: fluid buildup, internal bleeding, confusion, kidney failure, and more. Some of these medications can slow or even partially reverse liver scarring, while others are focused squarely on keeping dangerous complications at bay. The landscape is broad, and getting the right medications at the right time can meaningfully change outcomes.
Treating the Underlying Cause
The single most impactful medication decision in cirrhosis is often treating whatever is driving the liver damage. When the cause is removed or controlled, the liver sometimes recovers to a degree that surprises even clinicians. The specific drugs depend entirely on the etiology.
Viral Hepatitis
For hepatitis C, direct-acting antivirals have transformed the picture. These oral regimens, typically lasting eight to twelve weeks, cure the virus in the vast majority of patients. After a sustained virologic response, markers of liver fibrosis tend to improve, though researchers still debate how much of that improvement reflects true reversal of scarring versus a reduction in inflammation that makes the liver appear less stiff on testing.1PubMed Central. Fibrosis regression following hepatitis C antiviral therapy Studies show improvement in fibrosis scores even in patients who also have metabolic liver disease alongside hepatitis C.2Clinical Therapeutics. Improved Liver Fibrosis Regression After Direct-Acting Antiviral Therapy in Hepatitis C Patients: A Comparison of Patients With and Without MASLD
Hepatitis B works differently because the virus is rarely cured outright. Instead, nucleoside or nucleotide analogs like entecavir and tenofovir suppress viral replication long-term. In patients with hepatitis B-related cirrhosis, sustained viral suppression has been linked to substantially better survival. One study found the five-year death rate was roughly 19% with antiviral treatment versus about 44% without it, and rates of decompensation dropped similarly.3PubMed Central. Antiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus Infection These are drugs patients typically stay on indefinitely.
Alcohol-Related Cirrhosis
Abstinence from alcohol is the most effective intervention, but achieving it is a medical challenge in its own right. Baclofen, a muscle-relaxant drug that acts on the central nervous system, has become one of the few pharmacologic options with evidence behind it in this population. In a landmark randomized trial, about 71% of patients with alcoholic liver cirrhosis who received baclofen achieved and maintained abstinence, compared with 29% on placebo, and the drug showed no liver-related side effects.4The Lancet. Baclofen in the treatment of alcohol dependence in patients with alcoholic liver cirrhosis: a randomised, double-blind, placebo-controlled trial A meta-analysis across patients with alcohol-related liver disease and cirrhosis found abstinence rates of roughly 55% to 63%, with only one serious adverse event reported and no cases of baclofen addiction.5PubMed. Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases Most other medications used for alcohol use disorder, like naltrexone and disulfiram, carry hepatotoxicity risks that make them tricky to use in people whose livers are already compromised.
Cholestatic Liver Disease
Primary biliary cholangitis, one of the main cholestatic conditions that can progress to cirrhosis, has two FDA-approved medications: ursodeoxycholic acid and obeticholic acid. Ursodeoxycholic acid is the first-line treatment, but up to 40% of patients do not respond adequately to it.6PubMed Central. Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives For those patients, obeticholic acid has been shown to produce meaningful reductions in alkaline phosphatase and bilirubin levels, key markers of disease activity, on top of background ursodeoxycholic acid therapy.7PubMed. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis Additional agents targeting different receptor pathways are under investigation for patients who remain undertreated.
Metabolic Liver Disease
The fastest-growing cause of cirrhosis worldwide is metabolic dysfunction-associated steatotic liver disease, previously called nonalcoholic fatty liver disease. Resmetirom became the first drug approved specifically for this condition with fibrosis, but the medication landscape is still evolving. GLP-1 receptor agonists, originally developed for diabetes, have drawn attention because of large observational data suggesting they may lower the risk of progressing to cirrhosis compared with other diabetes medications. One study found that GLP-1 receptor agonist use was associated with a lower rate of developing cirrhosis in patients who did not already have it. However, the same study found no benefit in patients who had already progressed to cirrhosis.8JAMA Network. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease That distinction matters: these drugs may help prevent cirrhosis more than treat it.
Beta-Blockers for Portal Hypertension
As cirrhosis progresses, scar tissue increases resistance to blood flow through the liver, causing pressure to build in the portal vein system. This portal hypertension is the root cause of many of the most dangerous complications, including variceal bleeding and ascites. Non-selective beta-blockers have been a cornerstone of managing this pressure for decades, and carvedilol has emerged as the preferred agent. It acts on both the hyperdynamic circulation that drives portal pressure and on the increased resistance within the liver itself, giving it a dual mechanism that traditional beta-blockers like propranolol lack. Studies have found carvedilol more effective than propranolol at lowering portal pressure, and in preventing a first variceal bleed, it has performed better than endoscopic banding of varices.9PubMed. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension
Carvedilol is not without caveats. It lowers blood pressure more than traditional beta-blockers, which can be a problem in patients with very advanced cirrhosis who already run low blood pressures. Clinicians often start at low doses and titrate carefully. In patients with refractory ascites or spontaneous bacterial peritonitis, beta-blocker use requires close monitoring because the blood-pressure-lowering effect can worsen kidney function in this fragile group.
Acute Variceal Bleeding
When varices rupture and a patient is actively bleeding, the treatment is urgent and combines endoscopy with vasoactive drugs. The two most commonly used agents are terlipressin and octreotide. Terlipressin works by constricting blood vessels in the gut, reducing portal pressure in a sustained way. Compared with using no vasoactive drug, terlipressin nearly tripled the odds of controlling bleeding within 48 hours and cut in-hospital mortality by about two-thirds.10PubMed Central. Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials Octreotide, a synthetic hormone analog, appears to control bleeding within the first 24 hours more effectively than terlipressin alone in some analyses, but terlipressin offers advantages in sustained pressure reduction and hemodynamic stability.11PubMed Central. Choosing the Right Vasoactive Agent in Acute Variceal Bleeding in Cirrhotic Patients: A Review of Terlipressin vs. Octreotide Outcomes Neither drug alone is as effective as pairing it with endoscopic variceal ligation; the combination reduces five-day treatment failure dramatically compared with medication alone.12PubMed Central. Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials Terlipressin is not available everywhere, which is why octreotide remains a critical alternative in many settings.
Diuretics for Ascites
Ascites, the accumulation of fluid in the abdomen, is one of the hallmarks of decompensated cirrhosis. The standard first-line treatment is a combination of spironolactone, which blocks the hormone aldosterone, and furosemide, a loop diuretic. Guidelines from major liver societies recommend starting with spironolactone at 100 mg daily, with or without furosemide at 40 mg daily, maintaining roughly a 5-to-2 ratio between the two to keep potassium levels balanced.13AGA Advances. Aldosterone Antagonist Dosing and the Risk of Hyponatremia in Patients With Cirrhosis and Ascites
This regimen sounds straightforward, but the monitoring is anything but. Spironolactone at doses of 100 mg or higher has been associated with a roughly threefold increase in the risk of developing low sodium levels, regardless of how much furosemide is given alongside it.14AGA Advances. Aldosterone Antagonist Dosing and the Risk of Hyponatremia in Patients With Cirrhosis and Ascites Hyponatremia in cirrhosis is not a trivial lab finding; it worsens confusion, increases fall risk, and can complicate eligibility for liver transplant. Regular blood work to check electrolytes and kidney function is essential whenever diuretics are adjusted.
Spontaneous Bacterial Peritonitis and the Role of Albumin
Spontaneous bacterial peritonitis, a bacterial infection of ascitic fluid, is treated with intravenous antibiotics, most commonly a third-generation cephalosporin. But a pivotal trial showed that adding intravenous albumin to antibiotic treatment made a dramatic difference: kidney impairment developed in about 10% of patients who received both, versus a third of those who received antibiotics alone. Hospital mortality was also roughly cut in half.15PubMed. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis A meta-analysis of five trials confirmed the mortality benefit, finding that 30-day mortality was about 14% in groups receiving albumin compared with about 30% without it.16PubMed Central. Efficacy of Intravenous Albumin for Spontaneous Bacterial Peritonitis Infection Among Patients With Cirrhosis: A Meta-Analysis of Randomized Control Trials Albumin works here not as a volume expander in the simple sense but by supporting blood flow to the kidneys, which are already vulnerable in advanced cirrhosis. This combination of antibiotics plus albumin is now standard of care.
Hepatic Encephalopathy
When the liver can no longer clear ammonia and other toxins from the blood efficiently, they reach the brain and cause a spectrum of cognitive problems, from subtle attention deficits to deep confusion and coma. The two primary medications for hepatic encephalopathy are lactulose and rifaximin, and they work in complementary ways.
Lactulose is a synthetic sugar that the body cannot digest. It passes intact into the colon, where gut bacteria ferment it, lowering the pH of the intestinal environment. This acidic shift reduces ammonia production and absorption, and also promotes the growth of beneficial bacteria while discouraging those that produce ammonia.17PubMed Central. Lactulose in cirrhosis: Current understanding of efficacy, mechanism, and practical considerations It also has a laxative effect that physically clears ammonia-laden stool. Dose titration matters: the goal is typically two to three soft bowel movements per day, and over- or under-dosing is a common problem.
Rifaximin, a minimally absorbed antibiotic, is generally added on top of lactulose rather than replacing it. In a landmark trial, rifaximin reduced the risk of a hepatic encephalopathy episode by about 58% over six months compared with placebo, with breakthrough episodes occurring in roughly 22% of the rifaximin group versus 46% of the placebo group. Hospitalizations involving encephalopathy were also halved.18PubMed. Rifaximin treatment in hepatic encephalopathy More than 90% of patients in that trial were also on lactulose, so the benefit was additive. A Cochrane review found that the combination of rifaximin with a non-absorbable disaccharide like lactulose likely reduces mortality compared with lactulose alone, while rifaximin on its own does not appear to lower death rates.19Cochrane Database of Systematic Reviews. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis A network meta-analysis also confirmed that rifaximin significantly reduces recurrence in patients who have already recovered from an episode.20PubMed Central. Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis
Hepatorenal Syndrome
Hepatorenal syndrome is a form of kidney failure triggered by the severely disrupted circulation in advanced cirrhosis. The kidneys themselves are structurally normal; they are failing because blood flow has been shunted away from them. Treatment involves vasoconstrictors to redirect blood flow, combined with albumin to expand blood volume.
Terlipressin paired with albumin is the best-studied regimen. In a large randomized trial, about 32% of patients receiving terlipressin achieved verified reversal of hepatorenal syndrome, compared with 17% on placebo. The effect was even more pronounced in patients with systemic inflammation, where the reversal rate reached 37% with terlipressin versus 6% with placebo.21PubMed. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome Norepinephrine, administered in an intensive care setting, is considered an equivalent alternative by recent guidelines.22PLOS ONE. Comparative efficacy of terlipressin and norepinephrine for treatment of hepatorenal syndrome-acute kidney injury: A systematic review and meta-analysis Where terlipressin is unavailable, a combination of midodrine, octreotide, and albumin is sometimes used, though it is less effective.23PubMed. Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury Even with the best medical therapy, hepatorenal syndrome carries a grim prognosis, and these treatments are often viewed as a bridge to liver transplant.
Pain Management and Drug Safety
One of the most common and surprisingly misunderstood medication questions in cirrhosis is what to take for pain. Many patients and even some clinicians assume acetaminophen is dangerous for the liver, but in cirrhosis without active heavy drinking, acetaminophen at reduced doses of up to 2 grams per day is considered safe.24PubMed. The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review The drugs that are genuinely dangerous here are the nonsteroidal anti-inflammatory drugs like ibuprofen and naproxen. These worsen kidney function in cirrhosis, blunt the body’s response to diuretics, and increase the risk of bleeding from varices and peptic ulcers.25PubMed Central. Pain management in the cirrhotic patient: the clinical challenge Opioids should be used sparingly if at all because they slow gut motility, worsen constipation, and can precipitate or worsen hepatic encephalopathy.
Beyond pain medications, cirrhosis fundamentally alters how the body processes many drugs. The liver’s main drug-metabolizing enzymes lose activity in proportion to disease severity. In patients with the most advanced cirrhosis, activity of CYP1A2 was reduced by about 72%, CYP2C19 by 84%, CYP3A by 70%, and CYP2D6 by about 58%.26PubMed Central. Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently These enzymes metabolize a huge portion of commonly prescribed drugs, from blood pressure medications to antidepressants. The practical consequence is that standard doses can build up to toxic levels in a cirrhotic patient’s bloodstream. Dose reductions, extended dosing intervals, and careful monitoring are the norm for many medications, and any new prescription in a person with cirrhosis should prompt a conversation about liver-adjusted dosing.
Cholestatic Pruritus
Itching that accompanies cholestatic liver disease is not garden-variety dry skin. It is driven by bile acids and other pruritogens accumulating in the blood and signaling itch receptors. The sensation can be maddening, interfering with sleep and daily life. Evidence-based treatments for this type of itch include bezafibrate, a PPAR agonist, and rifampicin, a PXR agonist that increases the breakdown and excretion of pruritogens.27Nature Reviews Gastroenterology & Hepatology. Mechanisms of pruritus in cholestasis: understanding and treating the itch A stepwise approach is usually recommended, starting with bile acid sequestrants like cholestyramine and escalating through rifampicin, naltrexone, and sertraline if earlier steps fail.28PubMed Central. Drug treatment of pruritus in liver diseases Newer therapies targeting lysophosphatidic acid and other itch mediators are in development.
Statins in Cirrhosis
There was a time when statins were reflexively avoided in anyone with liver disease, but that stance has shifted considerably. A meta-analysis of six randomized trials found that statin therapy was associated with a meaningful reduction in portal pressure, lowering the hepatic venous pressure gradient by an average of about 1.1 mmHg, and patients on statins were more likely to achieve a clinically significant hemodynamic response.29PubMed. Statin Therapy and Portal Pressure Reduction in Cirrhosis: A Systematic Review and Meta-Analysis That pressure drop is modest in absolute terms but adds to whatever reduction beta-blockers are already providing. The trial data have not yet shown clear reductions in hard endpoints like variceal bleeding or mortality, so statins are not a standalone treatment for portal hypertension. But for patients who already have an indication for a statin, clinicians are increasingly comfortable continuing it through compensated cirrhosis. Simvastatin has been the most studied agent in this context.
Portal Vein Thrombosis and Anticoagulation
Blood clots in the portal vein are a common complication of cirrhosis and portal hypertension. Anticoagulation aims to reopen the vein and prevent the clot from growing, which reduces the risk of complications like worsening varices and intestinal ischemia. Traditionally, low-molecular-weight heparin and vitamin K antagonists like warfarin were used, but direct oral anticoagulants have emerged as an alternative. They offer the convenience of fixed dosing and no requirement for routine lab monitoring, which is appealing in a population already burdened with frequent medical visits.30PubMed Central. Direct oral anticoagulants in the treatment of portal vein thrombosis in patients with portal hypertension Safety data in patients with advanced liver disease are still accumulating, and most guidelines restrict their use to patients with well-compensated cirrhosis.
Muscle Wasting and Nutritional Supplements
Sarcopenia, the loss of muscle mass, affects a large proportion of people with cirrhosis and worsens outcomes across the board, from recovery after transplant to susceptibility to infections. Branched-chain amino acid supplements have been studied as a way to counteract this. A meta-analysis found that these supplements reduced frailty scores and improved body mass index and quality of life in cirrhotic patients with sarcopenia. However, they did not improve objective measures of muscle strength like handgrip or gait speed, and they had no effect on disease severity scores.31PubMed Central. Branched-Chain Amino Acid Supplements for Sarcopenia in Liver Cirrhosis: A Systematic Review and Meta-analysis So while they may help patients feel better and maintain weight, they are not a standalone fix for the muscle problem. Adequate caloric and protein intake remains the foundation, and resistance exercise programs are increasingly recommended alongside nutritional strategies.
Vaccines and Immune Dysfunction
Cirrhosis disrupts immune function in ways that make patients vulnerable to infections and less responsive to vaccines. Standard vaccines recommended for people with cirrhosis include hepatitis A, hepatitis B, influenza, pneumococcal, and COVID-19 vaccines. The problem is that these patients often mount weaker immune responses, meaning standard vaccine doses may not provide the same level of protection as in the general population.32PubMed Central. Vaccine Responses in Patients with Liver Cirrhosis: From the Immune System to the Gut Microbiota For hepatitis B in particular, higher doses or additional booster shots are commonly used. Vaccinating early in the course of liver disease, before cirrhosis is advanced, yields better immune responses. If you have cirrhosis and have not reviewed your vaccination status with your doctor recently, it is worth doing so, because preventing an infection is far easier than treating one in a compromised liver.